SEERS Co (458870) Fair Value & Analysis
Healthcare · KR · Market cap 1.1T KRW
Fair value as of: Jul 21, 2026
From 23 valuation models · updated 20 days ago
Share price −32.0% over the past month.
A solid business, but screening 74% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (8,636 KRW). The favourable scenario is already priced in.
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (3,830 KRW to 8,636 KRW) leaves room in how you read the outcome.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
26‑month range 2,860 KRW – 63,000 KRW · fair‑value band 3,830 KRW – 8,636 KRW · the 23,000 KRW price screens above the 5,932 KRW fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
SEERS Co (458870) currently trades at 23,000 KRW, while our model-based Fair Value estimate is 5,932 KRW, implying the stock looks roughly 74.2% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, SEERS Co generated revenue of 76.6B KRW at a net margin of 39.7%. It earns a return on equity of 80.4%. Net debt stands at 438M KRW. Fundamentals as of Jul 21, 2026
Our scenario range runs from 3,830 KRW (bear case) to 8,636 KRW (bull case); at 23,000 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 64% below its 52-week high and 258% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -74%, 458870 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: Growth Earnings (19,065 KRW) versus Asset-Based (696.49 KRW). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 46
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
SEERS Co., Ltd. engages in the development, manufacturing, and sales of medical devices in South Korea. It offers wearable biosensor, electrocardiographic holter analyser, thermometer, pulse oximeter, monitoring dashboard, ward managing software, mobile monitoring software, medical AI, and medical adhesive material.
Full company description
SEERS Co., Ltd. engages in the development, manufacturing, and sales of medical devices in South Korea. It offers wearable biosensor, electrocardiographic holter analyser, thermometer, pulse oximeter, monitoring dashboard, ward managing software, mobile monitoring software, medical AI, and medical adhesive material. The company was formerly known as Seers Technology Co., LTD. The company was founded in 2009 and is headquartered in Pyeongtaek-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SEERS Co reported revenue of 48.2B KRW in FY2025 versus 1.4B KRW in FY2021, a compound +142.8%/yr. Reported net income was 16.1B KRW in FY2025.
458870 screens 74% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare SEERS Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SEERS Co (458870) overvalued or undervalued?
What is the fair value of 458870?
What is the quality score of 458870?
What is the revenue of SEERS Co (458870)?
What is the net profit margin of 458870?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track SEERS Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.